(Q43198289)

English

Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study

scientific article published on 11 January 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 November 2017

Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study (English)

1 reference

Europe PubMed Central

15 November 2017

0 references

invasive aspergillosis

1 reference

based on heuristic

inferred from title

Raoul Herbrecht

1

1 reference

Europe PubMed Central

15 November 2017

Werner J. Heinz

5

1 reference

Europe PubMed Central

15 November 2017

author name string

J Maertens

2

1 reference

Europe PubMed Central

15 November 2017

L Baila

3

1 reference

Europe PubMed Central

15 November 2017

M Aoun

4

1 reference

Europe PubMed Central

15 November 2017

R Martino

6

1 reference

Europe PubMed Central

15 November 2017

S Schwartz

7

1 reference

Europe PubMed Central

15 November 2017

A J Ullmann

8

1 reference

Europe PubMed Central

15 November 2017

L Meert

9

1 reference

Europe PubMed Central

15 November 2017

M Paesmans

10

1 reference

Europe PubMed Central

15 November 2017

O Marchetti

11

1 reference

Europe PubMed Central

15 November 2017

H Akan

12

1 reference

Europe PubMed Central

15 November 2017

L Ameye

13

1 reference

Europe PubMed Central

15 November 2017

M Shivaprakash

14

1 reference

Europe PubMed Central

15 November 2017

C Viscoli

15

1 reference

Europe PubMed Central

15 November 2017

language of work or name

0 references

publication date

11 January 2010

1 reference

Europe PubMed Central

15 November 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

15 November 2017

45

1 reference

Europe PubMed Central

15 November 2017

7

1 reference

Europe PubMed Central

15 November 2017

1227-1233

1 reference

Europe PubMed Central

15 November 2017

https://scigraph.springernature.com/pub.10.1038/bmt.2009.334

0 references

Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

21 January 2018

Invasive fungal infections in hematology: new trends

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

21 January 2018

Factors associated with overall and attributable mortality in invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

21 January 2018

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

21 January 2018

Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

21 January 2018

A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

21 January 2018

Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

21 January 2018

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

21 January 2018

Caspofungin: the first in a new class of antifungal agents

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

21 January 2018

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

21 January 2018

An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

21 January 2018

False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

21 January 2018

Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

21 January 2018

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

21 January 2018

Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

21 January 2018

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

21 January 2018

Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

21 January 2018

Changes in causes of death over time after treatment for invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

21 January 2018

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

21 January 2018

Comparison of caspofungin and amphotericin B for invasive candidiasis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

21 January 2018

A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

21 January 2018

The enzymatic basis of drug-drug interactions with systemic triazole antifungals.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

21 January 2018

Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

21 January 2018

Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

7 January 2021

based on heuristic

inferred from DOI database lookup

Caspofungin for the treatment of less common forms of invasive candidiasis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

7 January 2021

based on heuristic

inferred from DOI database lookup

Reply to Denning

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.334

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/BMT.2009.334

1 reference

Europe PubMed Central

15 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

15 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43198289&oldid=1983625299"